287 results match your criteria Microcystic Adnexal Carcinoma

Desmoplastic Trichoepithelioma With Pseudocarcinomatous Hyperplasia: A Folliculosebaceous Neoplasm in Young Persons.

Am J Dermatopathol 2021 Apr 21. Epub 2021 Apr 21.

UCSF Dermatopathology and Oral Pathology Service, University of California San Francisco, San Francisco, CA; Departments of Pathology and Dermatology, University of California San Francisco, San Francisco, CA; Department of Dermatology, Yale University School of Medicine, New Haven, CT; and Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA.

Abstract: Pseudocarcinomatous desmoplastic trichoepithelioma (PDTE) features verrucous squamous epidermal hyperplasia with a jagged undersurface overlying cords of follicular germinative cells in a fibrotic stroma. To date, only 5 cases have been reported. We identified 7 new PDTEs from 2 institutions and reviewed their clinical manifestations and immunohistochemical profile. Read More

View Article and Full-Text PDF

Microcystic adnexal carcinoma of the glabella in a liver transplant recipient.

JAAD Case Rep 2021 Apr 4;10:126-129. Epub 2020 May 4.

Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.

View Article and Full-Text PDF

Microcystic Adnexal Adenoma: The Benign Counterpart of Microcystic Adnexal Carcinoma.

Am J Dermatopathol 2021 May 5. Epub 2021 May 5.

Department of Dermatology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; and Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC.

Abstract: Microcystic adnexal carcinoma (MAC) is a low-grade malignant neoplasm of slow growth and low metastatic potential, but locally aggressive. Architecturally, MAC is usually a poorly circumscribed neoplasm that tends to extend deeply into the dermis and subcutaneous tissue. We present here a lesion in which the histopathologic study showed a well-demarcated nodular lesion involving the mid dermis and composed of small cystic keratinous structures, solid aggregates of pale squamous cells without cytologic atypia and ductal structures. Read More

View Article and Full-Text PDF

Mohs Surgery Outside Usual Indications: A Review.

Acta Dermatovenerol Croat 2020 Dec;28(7):210-214

Pedro Rodríguez-Jiménez, MD, Dermatology Department, Hospital Universitario de la Princesa, Madrid, Calle Diego de Leon 62, 28006 Madrid, Spain;

The body of literature supporting the use of Mohs micrographic surgery (MMS) in tumors outside the main indications (basal cell carcinoma, squamous cell carcinoma, dermatofibrosacroma protuberans, lentigo maligna) is constantly growing, but it is still based on case reports, case series, or at best institutional case series that focus on a single malignancy. Our aim in this review was to assess use of MMS in an array of rare tumors outside the usual indications. A review was performed using the MEDLINE database and the search engine ClinicalKey®. Read More

View Article and Full-Text PDF
December 2020

Microcystic Adnexal Carcinoma with Xanthomatous Reaction.

Acta Derm Venereol 2021 Apr 26;101(4):adv00436. Epub 2021 Apr 26.

Department of Dermatology, Kagoshima University, 890-8520 Kagoshima, Japan. E-mail:

View Article and Full-Text PDF

Expression of Hedgehog signalling molecules in microcystic adnexal carcinoma.

Clin Exp Dermatol 2021 Mar 13. Epub 2021 Mar 13.

Institute for Prevention and Occupational Medicine of the German Social Accident Insurances, Ruhr-University Bochum (IPA), Bochum, Germany.

Background: Microcystic adnexal carcinoma (MAC) is a rare skin neoplasm that has not been characterized on a molecular basis.

Aim: To assess expression profiles of Hedgehog (HH) signalling molecules in MAC and control tumours.

Methods: Immunohistochemistry was performed for Sonic Hedgehog (SHH), Indian Hedgehog (IHH), Patched 1 (PTCH1) and Smoothened (SMO) on patient MAC tissue (n = 26) and control tumour tissue, including syringoma (SyG; n = 11), trichoepithelioma (TE; n = 11) and basal cell carcinoma (BCC; n = 12) tissues. Read More

View Article and Full-Text PDF

Local Recurrence Rates of Skin Tumors After Resection With Complete Circumferential Peripheral and Deep Margin Assessment-Identification of High-Risk Entities.

Dermatol Surg 2021 02;47(2):e31-e36

All authors are affiliated with the Department of Dermatology, Eberhard-Karls-UniversityTübingen, Tübingen, Germany.

Background: The local recurrence rates of malignant skin tumors after micrographic controlled surgery using complete circumferential peripheral and deep margin assessment (CCPDMA) are reported to be low. However, in daily practice, tumor entities with a significantly higher recurrence rate are found.

Objective: The aim of the investigation was to identify these high-risk tumors to develop approaches for risk stratification. Read More

View Article and Full-Text PDF
February 2021

Facial microcystic adnexal carcinoma - treatment with a "jigsaw puzzle" advancement flap and immediate esthetic reconstruction: A case report.

World J Clin Cases 2021 Jan;9(3):607-613

Department ofPlastic Surgery, Peking Union Medical College Hospital, Beijing 100730, China.

Background: Microcystic adnexal carcinoma (MAC) is a rare malignant tumor of the skin that is commonly found on the face. It grows slowly and has a low mortality rate. However, for various reasons, including strong histological invasiveness, clinical inexperience and inadequate procedure design, immediate or permanent facial deformity may occur after surgical operations. Read More

View Article and Full-Text PDF
January 2021

MOHS micrographic surgery for head and neck nonmelanoma skin cancer: An approach for ENT surgeons.

Dermatol Ther 2021 Jan 21;34(1):e14661. Epub 2020 Dec 21.

FMUP-Faculty of Medicine, University of Porto, Porto, Portugal.

Surgery is the main approach for skin cancer, with Mohs micrographic surgery (MMS) allowing the highest cure rates, best esthetics and superior functional outcomes. Ear, nose, and throat (ENT) surgeons are often challenged with patients presenting skin cancer, needing appropriate expertise to its adequate management. This paper highlights the most important aspects of MMS, enabling ENT surgeons to become familiar with its fundamental aspects. Read More

View Article and Full-Text PDF
January 2021

Microcystic adnexal carcinoma of the head and neck: Characteristics, treatment, and survival statistics.

Dermatol Ther 2021 Jan 3;34(1):e14559. Epub 2020 Dec 3.

Dermatology and Pathology, Rutgers New Jersey Medical School, Newark, New Jersey, USA.

Studies on microcystic adnexal carcinoma (MAC) survival rates have been limited. This effort examines the association of patient demographics, treatment modalities, and tumor stage with overall survival (OS) in patients with MAC of the head and neck. All cases of MAC with primary sites of the skin of the head and neck, confirmed histologically, and diagnosed from 2004 to 2016 in the National Cancer Database, were analyzed. Read More

View Article and Full-Text PDF
January 2021

Sequencing of Sclerosing Microcystic Adenocarcinoma Identifies Mutational Burden and Somatic Variants Associated With Tumorigenesis.

Anticancer Res 2020 Nov;40(11):6375-6379

Division of Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, CT, U.S.A.

Background/aim: Sclerosing microcystic adenocarcinoma (SMA) is a rare oral cavity neoplasia, histologically resembling microcystic adnexal carcinoma (MAC) of the skin. Only nine SMA cases have been reported in the literature, frequently in the context of immunosuppression; SMA has not been recognized in the most recent WHO tumor classification. We sought to identify potential molecular mechanisms of tumorigenesis in a case of SMA relative to those known for MAC. Read More

View Article and Full-Text PDF
November 2020

An atypical presentation of extensive centrofacial microcystic adnexal carcinoma responding to radiation: A case report and review of the literature.

SAGE Open Med Case Rep 2020 26;8:2050313X20953114. Epub 2020 Sep 26.

Division of Dermatology, University of Saskatchewan, Regina, SK, Canada.

Microcystic adnexal carcinoma is a rare cutaneous neoplasm believed to arise from pluripotent keratinocytes capable of adnexal differentiation. Due to its insidious growth and appearance, diagnosis is often delayed. A deep incisional or excisional biopsy for histopathology is the gold standard for diagnosis. Read More

View Article and Full-Text PDF
September 2020

Desmoplastic Trichoepithelioma: Histopathologic and Immunohistochemical Criteria for Differentiation of a Rare Benign Hair Follicle Tumor From Other Cutaneous Adnexal Tumors.

Cureus 2020 Aug 12;12(8):e9703. Epub 2020 Aug 12.

Pathology, South Bend Medical Foundation, South Bend, USA.

Desmoplastic trichoepitheliomas (DTEs) are benign cutaneous neoplasms that originate from the hair follicle and exhibit a preference for the facial region. This type of neoplasm is characterized by accelerated growth, with vigorous histologic and immunohistochemical features that may be confused with other skin cancers. Thus, the objective of this study is to establish a definitive diagnosis that can be widely used. Read More

View Article and Full-Text PDF

Microcystic adnexal carcinoma with germinative follicular differentiation.

J Cutan Pathol 2021 Jan 5;48(1):123-127. Epub 2020 Nov 5.

Dermatology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.

Microcystic adnexal carcinoma (MAC) is a low-grade adnexal carcinoma with controversial lines of differentiation. We present here an example of MAC showing histopathologic findings of germinative follicular differentiation in the form of solid aggregates of trichoblastoma intermingled with neoplastic aggregates of MAC. Immunohistochemical findings, showing positivity for PHLDA1 and negativity for BerEp4 in neoplastic aggregates of trichoblastoma, also supported a germinative follicular differentiation. Read More

View Article and Full-Text PDF
January 2021

Mohs micrographic surgery: a treatment method for many non-melanocytic skin cancers.

Dermatol Online J 2020 Apr 15;26(4). Epub 2020 Apr 15.

Department of Dermatology, Baylor College of Medicine, Houston, TX.

Mohs micrographic surgery (MMS) is a breakthrough surgical technique that has changed the management of neoplasms in dermatology. Through continued practice and evolution, MMS now can successfully treat a variety of rare non-melanocytic cutaneous malignancies for which achieving remission and the optimal aesthetic result after surgery was previously challenging. Mohs micrographic surgery has utility for conditions besides melanoma. Read More

View Article and Full-Text PDF

Periocular skin cancer: Diagnosis and management.

Dis Mon 2020 Oct 27;66(10):101046. Epub 2020 Jun 27.

Division of Ophthalmology, NorthShore University Health System, 2050 Pfingsten Rd., Ste. 280, Glenview, IL 60026, United States; Department of Ophthalmology and Visual Science, University of Chicago, Chicago, IL, United States. Electronic address:

The periocular region sees high rates of cancer compared to the rest of the body and can be affected by several unique tumors. Treatment typically involves surgical excision, although adjunctive therapies and prognosis vary depending on the diagnosis. Basal cell carcinoma (BCC) is the most common malignancy affecting this region and should be excised promptly. Read More

View Article and Full-Text PDF
October 2020

Determinants of Microcystic Adnexal Carcinoma Management and Outcomes in British Columbia.

J Cutan Med Surg 2020 Sep/Oct;24(5):536-537. Epub 2020 Jun 25.

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

View Article and Full-Text PDF

Collision tumor of microcystic adnexal carcinoma and squamous cell carcinoma discovered on Mohs sections.

JAAD Case Rep 2020 Jun 18;6(6):479-481. Epub 2020 Apr 18.

Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas.

View Article and Full-Text PDF

Multifocal Recurrent Microcystic Adnexal Carcinoma.

J Craniofac Surg 2020 Oct;31(7):e665-e667

Division of Otolaryngology, Department of Surgery, The George Washington University, Washington, DC.

Microcystic adnexal carcinoma (MAC) is a rare and locally aggressive neoplasm with preponderance for local recurrence but rarely nodal or distant metastasis. A 38-year-old male was referred to our clinic for definitive treatment of known recurrent and concern for multifocal MAC from previous biopsy. The patient was treated with modified Mohs and reconstruction with an anterolateral thigh (ALT) free flap for tissue coverage. Read More

View Article and Full-Text PDF
October 2020

Morphologically high-grade microcystic adnexal carcinoma: a report of two cases.

Histopathology 2020 Sep 2;77(3):449-452. Epub 2020 Jul 2.

Department of Dermatopathology, St John's Institute of Dermatology, St Thomas' Hospital, London, UK.

Aims: Microcystic adnexal carcinoma is a distinctive sweat duct carcinoma of low-grade malignant potential with a risk for locally destructive growth and local recurrence. Distant metastases and disease-related mortality are exceptional. The histological hallmarks of these tumours are the diffusely infiltrative growth within the dermis, the frequent invasion of subcutaneous structures, the presence of perineurial invasion, and the bland cytological features. Read More

View Article and Full-Text PDF
September 2020

[Eccrine carcinoma: a diagnostic pitfall].

Ned Tijdschr Geneeskd 2020 03 19;164. Epub 2020 Mar 19.

Ziekenhuis Gelderse Vallei, afd. Chirurgie, Ede.

Background: The eccrine carcinoma is a rare form of skin adnexal malignancy, usually presenting as a locally invasive, solitary lesion in the head and neck region. Histopathologically and immunohistochemically, eccrine carcinomas are difficult to differentiate from cutaneous metastases of breast carcinomas. Unlike treatment of cutaneous metastasis, treatment of a solitary eccrine carcinoma entails excision, generally without systematic therapy. Read More

View Article and Full-Text PDF

Microcystic Adnexal Carcinoma of the Face Treated With Definitive Chemoradiation: A Case Report and Review of the Literature.

Adv Radiat Oncol 2020 Mar-Apr;5(2):301-310. Epub 2019 Dec 13.

Department of Radiation Oncology Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article and Full-Text PDF
December 2019

Dermoscopic pitfall: Microcystic adnexal carcinoma mimicking basal cell carcinoma.

Indian J Dermatol Venereol Leprol 2020 Mar-Apr;86(2):202-205

Department of Dermatology and Venereologym, All India Institute of Medical Sciences, New Delhi, India.

View Article and Full-Text PDF
December 2020

Microcystic adnexal carcinoma: report of rare cases.

Biosci Rep 2020 01;40(1)

Department of Psychiatry, First Clinical Medical College/First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.

Microcystic adnexal carcinoma (MAC) is a rare, locally aggressive malignant neoplasm that derives from cutaneous eccrine/apocrine glands. MAC is classified as an eccrine/apocrine gland tumor and usually occurs in the skin. Here, we characterized and compared two cases of MAC. Read More

View Article and Full-Text PDF
January 2020

Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas.

Mod Pathol 2020 06 19;33(6):1092-1103. Epub 2019 Dec 19.

Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.

Microcystic adnexal carcinoma is a locally aggressive sweat gland carcinoma characterized by its infiltrative growth and histopathologic overlap with benign adnexal tumors, often posing challenges to both diagnosis and management. Understanding the molecular underpinnings of microcystic adnexal carcinoma may allow for more accurate diagnosis and identify potential targetable oncogenic drivers. We characterized 18 microcystic adnexal carcinomas by targeted, multiplexed PCR-based DNA next-generation sequencing of the coding sequence of over 400 cancer-relevant genes. Read More

View Article and Full-Text PDF

State of the art of Mohs surgery for rare cutaneous tumors in the Spanish Registry of Mohs Surgery (REGESMOHS).

Int J Dermatol 2020 Mar 28;59(3):321-325. Epub 2019 Nov 28.

Hospital La Paz, Madrid, Spain.

Background: The use of Mohs micrographic surgery (MMS) for rare cutaneous tumors is poorly defined. We aim to describe the demographics, tumor presentation and topography, surgery characteristics and complications of MMS for rare cutaneous tumors in a national registry.

Methods: Prospective cohort study of patients treated with MMS in Spain between July 2013 and June 2018. Read More

View Article and Full-Text PDF

Approaches to Perineural, Lymphovascular, and Single-Cell Disease.

Dermatol Surg 2019 12;45 Suppl 2:S118-S128

Department of Dermatology, University of Pittsburgh, Pittsburgh, PA.

Background: Mohs micrographic surgeons should be adept in identifying and managing perineural invasion (PNI), lymphovascular invasion (LVI), and single-cell spread (SCS), features denoting high-risk behavior of basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC) and microcystic adnexal carcinoma (MAC).

Objective: The purpose of this article is to review the literature and guidelines regarding the diagnosis of PNI, LVI, and SCS in BCC, cSCC, and MAC and examine the role of advanced diagnostic studies, adjuvant therapy, and reconstructive techniques of these high-risk tumors.

Materials And Methods: We performed a literature search including the following terms: PNI, LVI, SCS, BCC, cSCC, keratinocyte carcinoma, MAC, sentinel lymph node biopsy, radiation, chemotherapy, and staging. Read More

View Article and Full-Text PDF
December 2019